Rinne U K, Sonninen V, Marttila R
Adv Neurol. 1975;9:383-92.
The effect of a new dopaminergic agonist, piribedil, was studied in 16 patients with Parkinson's disease and compared with placebo and L-DOPA. Piribedil appeared to have a moderate therapeutic effect that was significantly less than that of L-DOPA. Tremor appeared to be the main clinical feature to benefit. Nausea, vomiting, and somnolence were most frequent during the buildup of treatment and confusion and hallucinations during long-term treatment. Piribedil caused a significant decrease in probenecid-induced accumulation of HVA in the CSF, suggesting reduced turnover of endogenous dopamine in the brain. There was a significant relationship between dopamine receptor activation by piribedil and improvement of parkinsonian disability.
对一种新型多巴胺能激动剂吡贝地尔在16例帕金森病患者中进行了研究，并与安慰剂和左旋多巴进行了比较。吡贝地尔似乎具有中等治疗效果，明显低于左旋多巴。震颤似乎是受益的主要临床特征。在治疗初期恶心、呕吐和嗜睡最为常见，而在长期治疗期间则出现意识模糊和幻觉。吡贝地尔导致丙磺舒诱导的脑脊液中高香草酸蓄积显著减少，提示脑内内源性多巴胺周转减少。吡贝地尔对多巴胺受体的激活与帕金森病残疾的改善之间存在显著关系。
